Relationship between plasma homocysteine level and lipid profiles in a community-based Chinese population

Mohetaboer Momin\(^1\), Jia Jia\(^1\), Fangfang Fan\(^1\), Jianping Li\(^1\), Jingtao Dou\(^3\), Dafang Chen\(^2\), Yong Huo\(^1\) and Yan Zhang\(^1\)*

Abstract

**Background:** Previous studies established a possible link among hyperhomocysteinemia (HHcy), dyslipidemia, and atherosclerosis. However, there was limited epidemic data concerning the relation between HHcy and lipid profiles, especially in community-based Chinese populations. This study aim to investigate the association of plasma homocysteine (Hcy) level with lipid profiles in a Chinese community-based population without lipid-lowering treatment.

**Method:** A total of 4660 Chinese subjects from a cohort of the Shijingshan district in Beijing were included in the analysis. Plasma total Hcy, serum lipid files including total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) as well as relevant metabolic risk factors were measured. Multivariate regression models adjusting for age, gender, smoking, drinking, physical activity, vitamin B supplement, body mass index, fasting blood glucose level, serum creatinine, systolic and diastolic blood pressure were used to evaluate associations of Hcy and lipid profiles.

**Result:** Subjects were 56.75 ± 8.91 years old, and 38.15% were male. Median (IQR) Hcy was 11.98 (10.00–14.93) μmol/L, and 24.4% had HHcy (defined as Hcy ≥ 15 μmol/L). Mean (SD) baseline TC was 5.34 ± 0.98 mmol/L, LDL-C was 3.27 ± 0.81 mmol/L, and HDL-C was 1.43 ± 0.38 mmol/L. Median (IQR) of TG was 1.28 (0.91–1.85) mmol/L. In multivariable linear-regression analyses, lnHcy (ln transformation for Hcy) level was positively associated with lnTG (adjusted β = 0.075, SE = 0.021, \(P = 0.001\)). Using Hcy < 15 μmol/L as a reference, HHcy was independently associated with both lnTG (adjusted β = 0.056, SE = 0.020, \(P = 0.004\)) and lnHDL (adjusted β = −0.018, SE = 0.009, \(P = 0.038\)). In multivariable logistic-regression analyses, HHcy was associated with increasing risk of low HDL-C (HDL-C < 1.04 mmol/L; adjusted odds ratio [OR] = 1.406, 95% confidence interval [CI]: 1.143 – 1.728, \(P = 0.001\)) and hypertriglyceridemia (TG ≥ 1.7 mmol/L; adjusted OR = 1.293, 95% CI: 1.096–1.524, \(P = 0.002\)) after adjusting the confounders. However, there were no significant associations between Hcy and TC or LDL-C.

**Conclusion:** The present study showed that HHcy was independently associated with hypertriglyceridemia and low levels of HDL-C, which provides evidence that Hcy levels might affect HDL-C and TG metabolism.

**Keywords:** Homocysteine, High-density lipoprotein cholesterol, Triglycerides

* Correspondence: drzhy1108@163.com
\(^1\)Department of Cardiology, Peking University First Hospital, Beijing, China

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Hyperhomocysteinemia (HHcy) has been regarded as a new modifiable risk factor for cardiovascular disease (CVD) through various mechanisms, including vascular endothelium damage, stimulation of smooth muscle cell proliferation, enhanced low-density lipoprotein cholesterol (LDL-C) peroxidation and thrombosis activation [1, 2]. Previous studies also established that there was a possible link among HHcy, dyslipidemia and atherosclerosis. Regarding Hcy, an inverse association between this amino acid and lipoproteins, especially high-density lipoprotein cholesterol (HDL-C), has been well described in humans and various animal models of HHcy [3]. HHcy might also increase the risk of CVD in dyslipidemia patients [4–6]. Although the mechanism of the link is not thoroughly known, recent studies strongly demonstrated the importance of the metabolic balance between S-adenosylmethionine (SAM), S-adenosylhomocysteine (SAH), phosphatidylcholine (PC), phosphatidylethanolamine (PE) and choline in Hcy metabolism, hypolipoproteinemia, liver function, and CVD [3, 7]. Several studies relating HHcy to disturbed HDL-C metabolism showed that Hcy can reduce circulating HDL-C via inhibiting ApoA-I protein synthesis and enhance HDL-C clearance [8, 9]. However, there are limited epidemic data about the relationship between HHcy and lipid profiles, especially in community-based Chinese populations. This study aims to investigate the association of plasma Hcy level with lipid profiles in a Chinese community-based population without lipid-lowering treatment.

Methods
Subject
Participants were from an atherosclerosis cohort survey performed in the Gucheng and Pingguoyuan communities of the Shijingshan district in Beijing, China from December 2011 to April 2012. The methods and primary results of this survey have been reported elsewhere [10]. A total of 4,660 eligible participants aged 40 years old and above were included in this analysis, after excluding those with missing covariates and those under lipid-lowering treatment. The proposal was approved by the ethics committee of both Peking University and Peking University First Hospital, and all subjects signed informed consent before enrollment.

Data collection
Baseline data were collected by trained research staff according to a standard operating procedure. Each participant was interviewed using a standardized questionnaire designed specifically for the present study that provided information related to education status, medical history, body mass index (BMI), past and current medication use, and personal habits such as use of vitamin B (VB) supplements and exercise habits, as well as cigarette and alcohol consumption. Seated brachial blood pressure (BP) and pulse for each participant were obtained by trained researchers after subjects rested for 5 min; an Omron HEM-7117 electronic sphygmomanometer was used. The mean of three consecutive measurements was used in the analysis.

Blood sample collection and laboratory methods
After an overnight fast of at least 12 h, a venous blood sample was obtained from the forearm of each participant. Plasma samples were separated within 30 min of collection and were stored at −80 °C. Plasma Hcy was measured using an electrochemiluminescence method at Southern Medical University Nanfang Hospital National Clinical Research Center for Kidney Disease in Guangzhou. Serum total cholesterol (TC), LDL-C, HDL-C, triglycerides (TG), fasting blood glucose (FBG), and creatinine (Scr) at baseline were measured on a Roche C8000 Automatic Analyzer in the laboratory of Chinese PLA General Hospital. According to the China Adult Dyslipidemia Prevention Guide (2007 Edition) criteria [11], we defined TC ≥5.18 mmol/L as hypercholesterolemia, LDL-C ≥3.37 mmol/L as a high level of LDL-C, HDL-C <1.04 mmol/L as low HDL-C, and TG ≥1.7 mmol/L as hypertriglyceridemia. According to results from previous studies [12], Hcy ≥15 μmol/L is often defined as HHcy. Additionally, in the present study, 15 μmol/L was the cut-off value of the upper quartiles of Hcy, so we defined Hcy ≥15 μmol/L as HHcy and divided the participants into two groups (Hcy ≥15 μmol/L and Hcy < 15 μmol/L) for further analysis.

Statistical analysis
Categorical variables are expressed as numbers and percentages. Continuous variables are described using means with standard deviations for data with normal distribution, and medians with interquartile range (IQR) for non-normally distributed data. According to Hcy level, the participants were stratified into Hcy quartiles or two groups with cut-off value of 15 μmol/L. Univariate comparison was made between groups using the ANOVA test, and the χ2 test for categorical variables. The trend test (univariate analysis of each variate with Hcy quartiles) was used to test the linear trend of covariates with the increasing of Hcy. Multiple linear and logistic regression analysis adjusted for age, gender, smoking, alcohol drinking, VB supplement, BMI, FBG, pulse, physical activity, education level, BP and Scr was performed to assess the associations between each lipid profile and Hcy. All analyses were conducted using Empower(R) (www.empowerstats.com, X&Y solutions, inc. Boston MA). A P-value <0.05 was considered statistically significant.
Results
Subjects were 56.75 ± 8.91 years old, and 38.15% were male. The median (IQR) value of Hcy was 11.98 (10.00 – 14.93) μmol/L, and 24.4% of subjects had HHcy. In order to have an even distribution in each group, the subjects were divided into subgroups using Hcy quartiles (Q1: 4.66–9.99 μmol/L; Q2: 10.00–11.97 μmol/L; Q3: 11.98–14.92 μmol/L; and Q4: 14.93–141.47 μmol/L). The trend test showed that with higher Hcy grade, subjects were older, more males, more smokers and drinkers. Also, levels of TG, Scr, BP, pulse, BMI and the proportion of physically active subjects were significantly higher. In contrast, with increased Hcy grade, HDL-C level, education level and the proportion of patients who took VB supplements were lower. No differences were observed for FBG. These data are presented in Table 1.

Multivariable regression analysis was carried out to assess whether Hcy was independently associated with these lipid profiles by adjusting for likely confounders. Model 1 was univariate analysis, Model 2 adjusted age and gender, model 3 adjusted age, gender, smoking, alcohol drinking, VB supplement, BMI, FBG, pulse, physical activity, education level, BP and Scr. In multivariable linear-regression analyses, lnHcy was positively associated with the lnTG in both models (adjusted β in full model = 0.075, SE = 0.021, P = 0.001). lnHcy was negatively associated with lnHDL (β = −0.024, SE = 0.010, P = 0.021) after adjustment for age and sex, but the association turned statistically insignificant after adjustment for all confounders (β = −0.016, SE = 0.010, P = 0.115). Though similar inverse trends were seen for lnTC and lnLDL, these were not statistically significant.

When Hcy <15 μmol/L group was used as the reference, Hcy ≥15 μmol/L group was independently associated with lnTG (adjusted β in full model = 0.056, SE = 0.020, P = 0.004) and lnHDL (adjusted β in full model = −0.018, SE = 0.009, P = 0.038) as well. No positive associations were observed between HHcy and lnTC or lnLDL-C. These data are presented in Table 2.

Furthermore, HHcy was associated with increasing risk of low HDL-C (adjusted odds ratio [OR] in full model = 1.406, 95% confidence interval [CI]:1.143–1.728, P = 0.001) and hypertriglyceridemia (adjusted OR in full model = 1.293, 95% CI: 1.096–1.524, P = 0.002) in multivariable logistic-regression analyses. Similar significant findings were also found when analyzed the relation between lnHcy and low HDL-C and hypertriglyceridemia. However, there were no significant correlations between HHcy and hypercholesterolemia or high LDL-C. These data are presented in Table 3.

Discussion
The major findings of the present study are that HHcy status is independently associated with lower HDL-C and higher TG. The population of the present study was from a Chinese urban community. Compared to prior studies based on Chinese population, the lipid levels observed in this population are close to those reported in recent epidemic data [13–15]. The median level of Hcy was 11.98 μmol/L, which is comparable to other data [12].

The interaction between lipids and Hcy metabolism has been tested in several animal models for HHcy, hypercholesterolemia, or both [16–20]. There are also some invaluable clinical observations that demonstrate the possible link between Hcy and lipid metabolism pathways. Durdi et al. reported that in 126 myocardial infarction patients, Hcy was significantly and negatively correlated with HDL-C (P < 0.05, r = −0.93) and there was also a positive correlation between total Hcy and LDL-C (P < 0.05, r = 0.98) [21]. In 300 Indian subjects with proven coronary heart disease, Hcy was found to be positively associated with TG and VLDL-C, and negatively with HDL-C [22]. In 125 heterozygous familial hypercholesterolemia patients, Hcy (r = −0.370, P = 0.003) and methylenetetrahydrofolate reductase (MTHFR) TT genotype were associated with low HDL values [23]. Anan et al. reported similar results to those observed during the present study that Hcy is associated with TG and HDL-C, but not with TC nor LDL-C in 40 Japanese patients with diabetes [24]. Rosa et al. reported that Hcy correlates negatively with ApoA-I and with HDL-C in elderly rural subjects from Sicily [25]. Focusing on Chinese subjects, in 2058 Chinese consecutive coronary artery angiographic patients, Hcy was found to be negatively correlated with HDL-C (r = −0.148, P < 0.001) [4]. In northern Chinese subjects, the prevalence of HHcy in the combined hyperlipidemia (high TG combined high TG) group has been reported to be significantly higher than that in the control with an OR of 3.339 [26]. However, not all prior studies have found correlations between HHcy and lipid profiles. Yadav reported that there was no significant correlation between plasma Hcy and TC, HDL-C, and TG in 60 ischemic heart disease patients [27]. A study that enrolled 155 diabetes patients and found no significant association between Hcy and lipids either [28]. Importantly, most recent data including 18297 US adults from the Vary Large Database of Lipids indicate that, in unadjusted analysis, levels of LDL-C, non-HDL-C and HDL-C were lower whereas levels of TG and VLDL-C were higher in the highest Hcy quartile, but after adjusting confounders the associations disappeared [29]. Compared to the results from the present study, the VLDL-21 study included a general population with similar age, sex ratio, and the Hcy level. However, the lipid levels were much lower than those observed in the present study. Also, information of lipid-lowering medication, one of the most confounders, was uncertain in VLDL-21 study. In a multiple linear
regression model, only age, sex, HbA1c, insulin and Scr were adjusted. Other factors such as BMI, statin usage, VB supplement, drinking status, and physical activities weren't taken into account, which should partly explain the discrepancy between two studies.

In summary, while studies examining the association between HHcy and lipid profiles in humans have had mixed conclusions, the most consistent findings indicate that higher Hcy is associated with decreased serum HDL-C and increased TG, which are consistent with the results of the present study. Furthermore, we found that TC and LDL-C levels showed a downward trend in the HHcy group, but there is no significant difference. The clinical and epidemical data concerning correlations between Hcy and TC, LDL-C are very limited, indicating that more studies are needed. To the best of our knowledge, this was the largest study in Chinese population which could provide enough statistical power to evaluate the association of Hcy and lipid profiles. Besides, most prior researches were aimed at CVD patients or high risk patients, therefore, there is little reliable data about this phenomenon in community-based population. The population in the present study is community-based, which could provide more evidence for extrapolating the

### Table 1 Baseline Characteristics Stratified by Hcy quartiles

| Hcy (μmol/L) | Total | Q1 | Q2 | Q3 | Q4 | P-value | P for trend |
|--------------|-------|----|----|----|----|---------|-------------|
| Median (Min-Max) | 11.98 (4.66–141.47) | 8.83 (4.66–9.99) | 11.02 (10.00–11.97) | 13.23 (11.98–14.92) | 18.50 (14.93–141.47) | <0.001 | <0.001 |
| N            | 4660  | 1161 | 1169 | 1161 | 1169 |         |             |
| Age (year-old), mean ± SD | 56.75 ± 8.91 | 53.31 ± 7.41 | 56.28 ± 7.97 | 58.59 ± 9.21 | 58.82 ± 9.72 | <0.001 | <0.001 |
| Sex, N (%)   |       |     |     |     |     |       |             |
| Male         | 1778 (38.15%) | 117 (10.08%) | 319 (27.29%) | 533 (45.91%) | 809 (69.20%) | <0.001 | <0.001 |
| Female       | 2882 (61.85%) | 1044 (89.92%) | 850 (72.71%) | 628 (54.09%) | 360 (30.80%) | <0.001 | <0.001 |
| Scr (μmol/L), mean ± SD | 59.44 ± 14.23 | 57.22 ± 9.05 | 63.25 ± 11.66 | 69.08 ± 13.44 | 77.34 ± 17.78 | <0.001 | <0.001 |
| TC (mmol/L), mean ± SD | 5.34 ± 0.98 | 5.37 ± 0.99 | 5.40 ± 0.91 | 5.35 ± 0.97 | 5.23 ± 1.03 | <0.001 | <0.001 |
| TG (mmol/L), Median (IQR) | 1.28 (0.91–1.85) | 1.24 (0.88–1.84) | 1.25 (0.90–1.73) | 1.28 (0.94–1.81) | 1.35 (0.95–2.01) | <0.001 | <0.001 |
| HDL-C (mmol/L), mean ± SD | 1.43 ± 0.38 | 1.49 ± 0.36 | 1.47 ± 0.36 | 1.43 ± 0.38 | 1.36 ± 0.39 | <0.001 | <0.001 |
| LDL-C (mmol/L), mean ± SD | 3.27 ± 0.81 | 3.28 ± 0.81 | 3.32 ± 0.77 | 3.30 ± 0.81 | 3.19 ± 0.85 | <0.001 | 0.011 |
| FBG (mmol/L), mean ± SD | 6.16 ± 1.80 | 6.12 ± 1.80 | 6.20 ± 1.91 | 6.20 ± 1.85 | 6.10 ± 1.62 | 0.389 | 0.728 |
| BMI (Kg/m²), mean ± SD | 26.00 ± 3.37 | 25.86 ± 3.54 | 25.92 ± 3.31 | 26.07 ± 3.36 | 26.1 ± 3.28 | 0.130 | 0.019 |
| SBP (mmHg), mean ± SD | 133.89 ± 16.85 | 130.91 ± 16.34 | 132.90 ± 16.49 | 135.07 ± 16.91 | 136.65 ± 17.12 | <0.001 | <0.001 |
| DBP (mmHg), mean ± SD | 75.21 ± 9.95 | 74.48 ± 9.48 | 75.07 ± 9.85 | 74.85 ± 9.86 | 76.42 ± 10.47 | <0.001 | <0.001 |
| Pulse (bpm), mean ± SD | 78.51 ± 11.41 | 78.15 ± 10.36 | 78.25 ± 11.20 | 78.50 ± 11.61 | 79.13 ± 12.35 | 0.159 | 0.033 |
| Education level, N (%) |       |     |     |     |     |       |             |
| Elementary above | 4581 (98.30%) | 1150 (99.05%) | 1153 (98.63%) | 1137 (97.93%) | 1141 (97.60%) | 0.029 | 0.003 |
| Illiterate    | 79 (1.70%) | 11 (0.95%) | 16 (1.37%) | 24 (2.07%) | 28 (2.40%) |       |             |
| Smoking status, N (%) |       |     |     |     |     |       |             |
| Current and former | 1249 (26.80%) | 96 (8.27%) | 230 (19.67%) | 356 (30.66%) | 567 (48.50%) | <0.001 | <0.001 |
| Never         | 3411 (73.20%) | 1065 (91.73%) | 939 (80.33%) | 805 (69.34%) | 602 (51.50%) |       |             |
| Alcohol drinking, N (%) |       |     |     |     |     |       |             |
| Current and former | 1204 (25.84%) | 136 (11.71%) | 242 (20.70%) | 319 (27.48%) | 507 (43.37%) | <0.001 | <0.001 |
| Never         | 3456 (74.16%) | 1025 (88.29%) | 927 (79.30%) | 842 (72.52%) | 662 (56.63%) |       |             |
| Physical activity, N (%) |       |     |     |     |     |       |             |
| Once a week above | 3737 (80.43%) | 896 (77.24%) | 928 (79.66%) | 971 (83.85%) | 942 (80.79%) | <0.001 | 0.005 |
| Others        | 912 (19.57%) | 264 (22.76%) | 237 (20.34%) | 187 (16.15%) | 224 (19.21%) |       |             |
| Vitamin B supplement, N (%) |       |     |     |     |     |       |             |
| Once a week above | 386 (8.28%) | 137 (11.80%) | 105 (9.01%) | 77 (6.64%) | 67 (5.74%) | <0.001 | <0.001 |
| Others        | 4269 (91.72%) | 1024 (88.20%) | 1061 (90.99%) | 1083 (93.36%) | 1101 (94.26%) |       |             |

Abbreviations: TC Total cholesterol, TG Triglycerides, HDL-C High density lipoprotein cholesterol, LDL-C Low density lipoprotein cholesterol, Hcy Homocysteine, Scr Serum creatinine, BMI Body mass index, FBG Fasting blood glucose, SBP Systolic blood pressure, DBP Diastolic blood pressure, IQR Interquartile range
### Table 2: Multivariate linear regression for effects of Hcy on lipid profiles

|                      | Model 1 |         |         |         |         |         |         |
|----------------------|---------|---------|---------|---------|---------|---------|---------|
|                      | β (SE)  | P       | β (SE)  | P       | β (SE)  | P       |
| LnTG (mmol/L)        |         |         |         |         |         |         |
| LnHcy                | 0.102 (0.020) | <0.001 | 0.077 (0.022) | <0.001 | 0.075 (0.021) | 0.001 |
| Hcy < 15 μmol/L      | Ref.    | -       | Ref.    | -       | Ref.    | -       |
| Hcy ≥ 15 μmol/L      | 0.084 (0.018) | <0.001 | 0.061 (0.020) | 0.001 | 0.056 (0.020) | 0.004 |
| LnHDL-C (mmol/L)     |         |         |         |         |         |         |
| LnHcy                | −0.098 (0.010) | <0.001 | −0.024 (0.010) | 0.021 | −0.016 (0.010) | 0.115 |
| Hcy < 15 μmol/L      | Ref.    | -       | Ref.    | -       | Ref.    | -       |
| Hcy ≥ 15 μmol/L      | −0.082 (0.009) | <0.001 | −0.026 (0.010) | 0.003 | −0.018 (0.009) | 0.038 |
| LnTC (mmol/L)        |         |         |         |         |         |         |
| LnHcy                | −0.033 (0.007) | <0.001 | −0.002 (0.008) | 0.739 | −0.002 (0.008) | 0.771 |
| Hcy < 15 μmol/L      | Ref.    | -       | Ref.    | -       | Ref.    | -       |
| Hcy ≥ 15 μmol/L      | −0.029 (0.006) | <0.001 | −0.005 (0.006) | 0.486 | −0.006 (0.007) | 0.691 |
| LnLDL-C (mmol/L)     |         |         |         |         |         |         |
| LnHcy                | −0.044 (0.010) | <0.001 | −0.016 (0.011) | 0.095 | −0.018 (0.012) | 0.133 |
| Hcy < 15 μmol/L      | Ref.    | -       | Ref.    | -       | Ref.    | -       |
| Hcy ≥ 15 μmol/L      | −0.039 (0.009) | <0.001 | −0.017 (0.009) | 0.080 | −0.017 (0.010) | 0.071 |

Model 1 univariate analysis
Model 2 adjusted for age and sex
Model 3 adjusted for age, sex, education level, physical activity, vitamin B supplement, body mass index, pulse, fasting glucose, smoking status, drinking status, systolic blood pressure, diastolic blood pressure, serum creatinine

**Abbreviations:** TC Total cholesterol, TG Triglycerides, HDL-C High density lipoprotein cholesterol, LDL-C Low density lipoprotein cholesterol, Hcy Homocysteine

### Table 3: Multivariate Logistic Regression for Effects of Hcy on Dyslipidemia

|                      | Model 1 |         |         |         |         |         |         |
|----------------------|---------|---------|---------|---------|---------|---------|---------|
|                      | OR (95% CI) | P       | OR (95% CI) | P       | OR (95% CI) | P       |
| TG ≥ 1.70 (mmol/L)   |         |         |         |         |         |         |
| LnHcy                | 1.391 (1.192, 1.623) | <0.001 | 1.327 (1.117, 1.576) | 0.001 | 1.267 (1.051, 1.525) | 0.013 |
| Hcy < 15 μmol/L      | Ref.    | -       | Ref.    | -       | Ref.    | -       |
| Hcy ≥ 15 μmol/L      | 1.377 (1.195, 1.586) | <0.001 | 1.324 (1.136, 1.544) | <0.001 | 1.293 (1.096, 1.524) | 0.002 |
| HDL-C <1.04 (mmol/L) |         |         |         |         |         |         |
| LnHcy                | 2.167 (1.797, 2.614) | <0.001 | 1.301 (1.049, 1.614) | 0.017 | 1.277 (1.013, 1.613) | 0.039 |
| Hcy < 15 μmol/L      | Ref.    | -       | Ref.    | -       | Ref.    | -       |
| Hcy ≥ 15 μmol/L      | 2.114 (1.769, 2.526) | <0.001 | 1.401 (1.154, 1.701) | <0.001 | 1.406 (1.143, 1.728) | 0.001 |
| TC ≥ 5.18 (mmol/L)   |         |         |         |         |         |         |
| LnHcy                | 0.746 (0.645, 0.864) | <0.001 | 0.991 (0.840, 1.168) | 0.910 | 0.950 (0.798, 1.130) | 0.562 |
| Hcy < 15 μmol/L      | Ref.    | -       | Ref.    | -       | Ref.    | -       |
| Hcy ≥ 15 μmol/L      | 0.754 (0.660, 0.862) | <0.001 | 0.930 (0.804, 1.075) | 0.326 | 0.908 (0.779, 1.057) | 0.214 |
| LDL-C ≥ 3.37 (mmol/L)|         |         |         |         |         |         |
| LnHcy                | 0.770 (0.662, 0.894) | <0.001 | 0.906 (0.766, 1.072) | 0.250 | 0.904 (0.757, 1.080) | 0.265 |
| Hcy < 15 μmol/L      | Ref.    | -       | Ref.    | -       | Ref.    | -       |
| Hcy ≥ 15 μmol/L      | 0.716 (0.624, 0.821) | <0.001 | 0.869 (0.750, 1.007) | 0.061 | 0.910 (0.774, 1.071) | 0.256 |

Model 1 univariate analysis
Model 2 adjusted for age and sex
Model 3 adjusted for age, sex, education level, physical activity, vitamin B supplement, body mass index, pulse, fasting glucose, smoking status, drinking status, systolic blood pressure, diastolic blood pressure, serum creatinine

**Abbreviations:** TC Total cholesterol, TG Triglycerides, HDL-C High density lipoprotein cholesterol, LDL-C Low density lipoprotein cholesterol, Hcy Homocysteine
results to the general population. Additionally, most prior studies conducted univariate analysis or multivariate analysis adjusting for few confounders. Our study not only excluded subjects with lipid-lowering drugs which is one of the most important confounders, but also included many additional covariates such as FBG, BMI, kidney function, physical activity, among others.

There are many experimental foundations that provide support for the hypothesis that Hcy affects lipid metabolism. (1) Prior study results suggest the mechanisms for HHcy are mainly related to the down regulation of key players in HDL production (Apo-AI, lecithin-cholesterol acyltransferase (LCAT)) [30] and the reducing of the liver Apo-AI mRNA expression [31]. (2) The inhibition of PC conversion to PE and the low ratio of PE/PC caused by HHcy are key issues in the relationship between HHcy and triglycerides accumulation [32, 33]. (3) Hcy has been found to enhance the expression of sterol regulatory element-binding proteins (SREBPs) to increase intracellular accumulation of TC and TG [34]. (4) Hcy causes protein misfolding in the endoplasmic reticulum and oxidative stress, which might affect lipoprotein particle production [34–38]. (5) Global DNA hypomethylation has been suggested as a mechanism linking Hcy to lipid disorders and atherosclerosis in vascular smooth muscle cells [39]. (6) Plasma concentrations of TG have significantly important effects on the distribution of HDL subclasses, and HDL maturation might be abnormal and reverse cholesterol transport might be weakened in HTG patients [40]. Consequently, the findings in the present study might partially be explained by the interaction between TG and HDL-C.

The present study also has several limitations. It was a cross-sectional study, thus predictions about the incidence of dyslipidemia due to HHcy in the community-based population cannot be made from this study. Additionally, serum lipid profiles might relate to dietary habits that were not assessed in detail due to lack of such data. Further follow-up data in this cohort as well as independent replication are needed.

Conclusion
The present study showed that HHcy status is independently associated with hypertriglyceridemia and low HDL-C levels, which provides evidence that Hcy might affect HDL-C and TG metabolism.

Acknowledgements
The authors thank all study team members for their participation. We are especially grateful to the site managers of Gucheng and Pingguoyuan Community Health Centers for their supports.

Funding
This study was supported by a grant from the University of Michigan-Peking University Health Science Center (UM-PUHSC) joint institute for translational and clinical research (grant No: BMU20110177).

Availability of data and materials
We are sorry to inform you that we cannot accept the data sharing policy due to the lack of consent from other cooperating research partners.

Authors’ contributions
MM participated in the design of the study, performed the statistical analysis, and drafted the manuscript. JX participated in the epidemiological survey, data management, and helped to draft the manuscript. JD participated in collecting blood samples and conducting the lipid testing. JL and YH participated in the study design and helped to draft the manuscript. DC participated in data management and helped with statistical analysis. FF participated in implementing the investigation, data analysis, and drafting the manuscript. YZ, who is principal investigator of this study, conceived of the study, and participated in its design and coordination, and helped to analyze data and draft the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Not applicable.

Ethics approval and consent to participate
The proposal was approved by the ethics committee of Peking University and Peking University First Hospital, and all subjects signed informed consent before enrollment. We adhered to the principles of the Declaration of Helsinki. The procedures followed were in accordance with institutional guidelines.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Cardiology, Peking University First Hospital, Beijing, China. 2Department of Epidemic & Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China. 3Department of Endocrinology, Chinese People’s Liberation Army (PLA) General Hospital, Beijing, China.

Received: 10 August 2016 Accepted: 2 March 2017
Published online: 14 March 2017

References
1. Antoniades C, Antonopoulos AS, Tousoulis D, Marinou K, Stefanadis C. Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J. 2002;23(1):16–15.
2. Wierzbicki AS. Homocysteine and cardiovascular disease: a review of the evidence. Diab Vasc Dis Res. 2007;2007:143.
3. Obeid R, Herrmann W. Homocysteine and lipids: S-adenosyl methionine as a key intermediate. FEBS Lett. 2009;583(8):1215–25.
4. Xiao Y, Zhang Y, Lv X, et al. Relationship between lipid profiles and plasma total homocysteine, cysteine and the risk of coronary artery disease in coronary angiographic subjects. Lipids Health Dis. 2011;10:137.
5. Herrmann W, Obeid R, Hubner U, Journa M, Geisel J. Homocysteine in relation to C-reactive protein and low-density lipoprotein cholesterol in assessment of cardiovascular risk. Cell Mol Biol (Noisy-le-grand). 2004;50(8):895–901.
6. Daly C, Fitzgerald AP, O’Callaghan P, Collins P, Cooney MT, Graham IM. Homocysteine increases the risk associated with hyperlipidaemia. Eur J Cardiovasc Prev Rehabil. 2009;16(2):150–5.
7. Barter PJ, Rye KA. Homocysteine and cardiovascular disease: is HDL the link? Circ Res. 2006;99(6):565–6.
8. Liao D, Tan H, Hui R, et al. Hyperhomocysteinemia decreases circulating high-density lipoprotein by inhibiting apolipoprotein A-I protein synthesis and enhancing HDL cholesterol clearance. Circ Res. 2006;99(6):598–606.
9. Devlin AM, Lentz SR. ApoA-I: a missing link between homocysteine and lipid metabolism? Circ Res. 2006;98(4):431–3.
10. Fan F, Qi L, Jia J, et al. Noninvasive Central Systolic Blood Pressure Is More Strongly Related to Kidney Function Decline Than Peripheral Systolic Blood Pressure in a Chinese Community-Based Population. Hypertension. 2016;67(6):166–72.

11. China Adult Dyslipidemia Prevention Guideline. Chin J Cardiol. 2007;35(5):300–419.

12. Yang B, Fan S, Zhi X, et al. Prevalence of hyperhomocysteinemia in China: a systematic review and meta-analysis. Nutrients. 2015;7(1):74–90.

13. Wang X, Ye P, Cao R, et al. Triglycerides are a predictive factor for arterial stiffness: a community-based 4.8-year prospective study. Lipids Health Dis. 2016;15:97.

14. Song Q, Liu X, Wang A, et al. Associations between non-traditional lipid measures and risk for type 2 diabetes mellitus in a Chinese community population: a cross-sectional study. Lipids Health Dis. 2016;15:70.

15. Jiang B, Li B, Wang Y, et al. The nine-year changes of the incidence and characteristics of metabolic syndrome in China: longitudinal comparisons of the two cross-sectional surveys in a newly formed urban community. Cardiovasc Diabetol. 2016;15(1):84.

16. Watanabe M, Osada J, Aratani Y, et al. Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocysteinemia. Proc Natl Acad Sci U S A. 1995;92(5):1585–9.

17. Namekata K, Enokido Y, Ishii I, Nagai Y, Harada T, Kimura H. Abnormal lipid metabolism in cystathionine beta-synthase-deficient mice, an animal model for hyperhomocysteinemia. J Biol Chem. 2004;279(51):52961–9.

18. Wang H, Jiang X, Yang F, et al. Hyperhomocysteinemia accelerates atherosclerosis in cystathionine beta-synthase and apolipoprotein E double knockout mice with and without dietary perturbation. Blood. 2003;101(10):3901–7.

19. Mikael LG, Wang XL, Wu Q, Jiang H, Maclean KN, Rozen R. Hyperhomocysteinemia is associated with hypertrygliceridemia in mice with methylenetetrahydrofolate reductase deficiency. Mol Genet Metab. 2009;98(1–2):87–94.

20. Frauscher G, Karnauchova E, Muehl A, Hoeger H, Lubec B. Oral administration of homocysteine leads to increased plasma triglycerides and homocysteic acid-additional mechanisms in homocysteine induced endothelial damage? Life Sci. 1995;57(8):813–7.

21. Ounis PA, Sood SK, Pfeifer SI, et al. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood. 1999;94(3):956–67.

22. Cox JS, Chapman RE, Walter P. The unfolded protein response coordinates the production of endoplasmic reticulum protein and endoplasmic reticulum membrane. Mol Biol Cell. 1997;8(9):1805–14.

23. Doerter WT, Lehmann MA. Regulation of the dolichol pathway in human fibroblasts by the endoplasmic reticulum unfolded protein response. Proc Natl Acad Sci U S A. 1999;96(23):13050–5.

24. Anan F, Masaki T, Umeno Y, et al. Correlations between hyperhomocysteinemia levels and atherosclerosis in Japanese type 2 diabetic patients. Metabolism. 2007;56(10):1390–5.

25. Gueant-Rodriguez RM, Spada R, Moreno-Garcia M, et al. Homocysteine is a determinant of ApoA-I and both are associated with ankle brachial index, in an ambulatory elderly population. Atherosclerosis. 2011;214(2):480–5.

26. Huang L, Song XM, Zhu WL, Li Y. Plasma homocysteine and gene polymorphisms associated with the risk of hyperlipidemia in northern Chinese subjects. Biomed Environ Sci. 2008;21(6):514–20.

27. Yadav AS, Bhagwat VR, Rathod IM. Relationship of plasma homocysteine with lipid profile parameters in ischemic heart disease. Indian J Clin Biochem. 2006;21(1):106–10.

28. de Luis DA, Fernandez N, Arranz ML, Aller R, Izaza O, Romero E. Total homocysteine levels relation with chronic complications of diabetes, body composition, and other cardiovascular risk factors in a population of patients with diabetes mellitus type 2. J Diabetes Complications. 2005;19(1):42–6.

29. Lupton JR, Quispe R, Kulkarni K, Martin SS, Jones SR. Serum homocysteine is not independently associated with an atherogenic lipid profile: The Very Large Database of Lipids (VLDL-21) study. Atherosclerosis. 2006;194(3):564–69.

30. Velez-Carrasco W, Mielke M, Twiss CO, Smith JD. Dietary methionine effects on plasma homocysteine and HDL metabolism in mice. J Nutr Biochem. 2008;19(6):362–70.

31. Mikael LG, Genest Jr. J, Rozen R. Elevated homocysteine reduces apolipoprotein A-I expression in hyperhomocysteinemic mice and in males with coronary artery disease. Circ Res. 2006;98(4):564–71.

32. Nishimaki-Mogami T, Suzuki K, Takahashi A. The role of phosphatidylethanolamine methylation in the secretion of very low density lipoproteins by cultured rat hepatocytes: rapid inhibition of phosphatidylethanolamine methylation by bezafibrate increases the density of apolipoprotein B48-containing lipoproteins. Biochim Biophys Acta. 1996;1304(1):21–31.

33. Nishimaki-Mogami T, Yao Z, Fujimori K. Inhibition of phosphatidylcholine synthesis via the phosphatidylethanolamine methylation pathway impairs incorporation of bulk lipids into VLDL in cultured rat hepatocytes. J Lipid Res. 2002;43(7):1035–45.

34. Westrock GH, Lentz SR, Dayal S, et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest. 2001;107(10):1263–73.

35. Thampi P, Stewart BW, Joseph L, Melnyk SB, Hennings LJ, Nagarajan S. Dietary homocysteine promotes atherosclerosis in apoE-deficient mice by inducing scavenger receptors expression. Atherosclerosis. 2008;197(2):620–9.

36. Ounis PA, Sood SK, Pfeifer SI, et al. Homocysteine-induced endoplasmic reticulum stress and growth arrest leads to specific changes in gene expression in human vascular endothelial cells. Blood. 1999;94(3):956–67.

37. Cox JS, Chapman RE, Walter P. The unfolded protein response coordinates the production of endoplasmic reticulum protein and endoplasmic reticulum membrane. Mol Biol Cell. 1997;8(9):1805–14.

38. Doerter WT, Lehmann MA. Regulation of the dolichol pathway in human fibroblasts by the endoplasmic reticulum unfolded protein response. Proc Natl Acad Sci U S A. 1999;96(23):13050–5.

39. Yideng J, Jianzhong Z, Ying H, et al. Homocysteine-mediated expression of SAHH, DNMTs, MB2D, and DNA hypomethylation potential pathogenic mechanism in VSMCs. DNA Cell Biol. 2007;26(8):603–11.

40. Tian L, Fu M. The relationship between high density lipoprotein subclass profile and plasma lipids concentrations. Lipids Health Dis. 2010;9:118.